Panagiotis Skouras

Dr. Panagiotis Skouras

National and Kapodistrian University of Athens, Athens, Attikí, Greece
orcid
Medical Doctor specializing in Family Medicine with a strong...

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
Antonios N. GargalionisAntonios N. Gargalionis
Antonios N. Gargalionis
Christina PiperiChristina Piperi
Christina Piperi
Exosomes constitute small extracellular vesicles that contain lipids, proteins, nucleic acids, and glycoconjugates from the secreted cells and are capable of transmitting signals between cells and coordinating cellular communication. By this means, they are ultimately involved in physiology and disease, including development, homeostasis, and immune system regulation, as well as contributing to tumor progression and neurodegenerative diseases pathology. Recent studies have shown that gliomas secrete a panel of exosomes which have been associated with cell invasion and migration, tumor immune tolerance, potential for malignant transformation, neovascularization, and resistance to treatment. Exosomes have therefore emerged as intercellular communicators, which mediate the tumor–microenvironment interactions and exosome-regulated glioma cell stemness and angiogenesis. They may induce tumor proliferation and malignancy in normal cells by carrying pro-migratory modulators from cancer cells as well as many different molecular cancer modifiers, such as oncogenic transcripts, miRNAs, mutant oncoproteins, etc., which promote the communication of cancer cells with the surrounding stromal cells and provide valuable information on the molecular profile of the existing tumor. Moreover, engineered exosomes can provide an alternative system for drug delivery and enable efficient treatment. In the present review, we discuss the latest findings regarding the role of exosomes in glioma pathogenesis, their utility in non-invasive diagnosis, and potential applications to treatment.

24 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
MMMarkouli Mariam
Markouli Mariam
Theodosis KalamatianosTheodosis Kalamatianos
Theodosis Kalamatianos
GSGeorge Stranjalis
George Stranjalis
PKPenelope Korkolopoulou
Penelope Korkolopoulou
Christina PiperiChristina Piperi
Christina Piperi
Gliomas comprise the most frequent primary central nervous system (CNS) tumors, characterized by remarkable genetic and epigenetic heterogeneity, difficulty in monitoring, and increased relapse and mortality rates. Tissue biopsy is an established method of tumor cell collection and analysis that enables diagnosis, classification of different tumor types, and prediction of prognosis upon confirmation of tumor’s location for surgical removal. However, it is an invasive and often challenging procedure that cannot be used for frequent patient screening, detection of mutations, disease monitoring, or resistance to therapy. To this end, the minimally invasive procedure of liquid biopsy has emerged, allowing effortless tumor sampling and enabling continuous monitoring. It is considered a novel preferable way to obtain faster data on potential tumor risk, personalized diagnosis, prognosis, and recurrence evaluation. The purpose of this review is to describe the advances on liquid biopsy for glioma diagnosis and management, indicating several biomarkers that can be utilized to analyze tumor characteristics, such as cell-free DNA (cfDNA), cell-free RNA (cfRNA), circulating proteins, circulating tumor cells (CTCs), and exosomes. It further addresses the benefit of combining liquid biopsy with radiogenomics to facilitate early and accurate diagnoses, enable precise prognostic assessments, and facilitate real-time disease monitoring, aiming towards more optimal treatment decisions.

7 February 2023 in Environmental Research
Verified
Journal Article
Closed access
Dardiotis EfthimiosDardiotis Efthimios
Dardiotis Efthimios
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
OVOrfeas-Petros Varvarelis
Orfeas-Petros Varvarelis
Athina-Maria AloizouAthina-Maria Aloizou
Athina-Maria Aloizou
AHAntonio Hernández
Antonio Hernández
GHGeorgios M. Hadjigeorgiou
Georgios M. Hadjigeorgiou

22 January 2025 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
MMMarkouli Mariam
Markouli Mariam
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
Christina PiperiChristina Piperi
Christina Piperi

27 September 2025 in Neurotherapeutics
Verified
Journal Article
Open access
AGAngeliki-Ioanna Giannopoulou
Angeliki-Ioanna Giannopoulou
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
PSPanagiotis Sarantis
Panagiotis Sarantis
AAAlkinoos Armoundas
Alkinoos Armoundas
KPKostas Palamaris
Kostas Palamaris
Christina PiperiChristina Piperi
Christina Piperi
Gliomas exhibit diverse genetic, molecular, and histological profiles with limited liquid biopsy biomarkers. Loss of Long Interspersed Nuclear Element-1 (LINE-1) methylation confers to genomic instability and tumorigenesis, primarily mediated by DNA methyltransferase 1 (DNMT1) through interaction with histone H4 lysine 20 trimethylation (H4K20me3) and histone H3 lysine 9 trimethylation (H3K9me3). The present study evaluates the utility of liquid biopsy in detecting LINE-1 methylation in gliomas and potential correlations with DNMT1, H4K20me3, H3K9me3 tissue levels, clinicopathological characteristics and patients' survival. LINE-1 methylation was measured in cell-free DNA (cfDNA) of glioma patients' plasma prior to surgery or any adjuvant therapy and age-matched controls as well as in glioma tissues along with DNMT1, H4K20me3 and H3K9me3 expression. LINE-1 methylation content in plasma cfDNA and tissue samples was decreased significantly in grade 4 gliomas compared to controls (p ​< 0.0001, respectively). Similarly, DNMT1, H4K20me3 and H3K9me3 expression was significantly reduced in grade 4 cases compared to grade 2 (p ​< 0.0001). cfLINE-1 methylation was positively correlated with tissue LINE-1 methylation levels (p ​= 0.036) as well as with DNMT1 and H4K20me3 tissue expression in grade 4 samples (p ​< 0.0001, respectively). Moreover, low LINE-1 methylation plasma levels and tissue expression of DNMT1, H4K20me3 and H3K9me3 were correlated with worse overall survival in the entire cohort (p ​= 0.041, ​p ​= 0.016, ​p ​< 0.0001, ​p ​= 0.001, respectively). The present study supports the utility of liquid biopsy for the detection of LINE-1 hypomethylation, as a complementary prognostic biomarker for grade 4 tumors.

1 November 2024 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
Panagiotis SkourasPanagiotis Skouras
Panagiotis Skouras
TKTheodosis Kalamatianos
Theodosis Kalamatianos
MMMariam Markouli
Mariam Markouli
AKAngelos Karagiannis
Angelos Karagiannis
LSLampis C. Stavrinou
Lampis C. Stavrinou
Introduction: Aneurysmal subarachnoid hemorrhage (aSAH) is a type of non-traumatic SAH that can have detrimental effects on the central nervous system, resulting in severe disability or death. Methods: Early nimodipine is currently the only strongly recommended pharmacological treatment that has shown efficacy in improving neurological/functional outcomes in aSAH patients. Whether statin treatment is of benefit to aSAH patients is an issue that has generated considerable interest and debate. In the present scoping review, we mapped and analyzed the available literature on metaanalyses of randomized clinical trials (RCTs) examining the effect of statins on aSAH. Seventeen meta-analyses of RCTs, published between 2008 and 2023, were identified. Results: Treatments in included meta-analyses were based on various regimens of simvastatin, pravastatin, pitavastatin or atorvastatin for up to 21 days. Eleven of the included reports indicated some beneficial effect of statin treatment, reducing rates of at least one of the following: cerebral vasospasm, delayed cerebral ischemia/delayed ischemic neurologic deficit, mortality or functional/ neurological outcome. In contrast, six meta-analyses, showed no such effects. Conclusion: The limitations reported by several meta-analyses, included low patient numbers or disproportionate representation of patients from certain RCTs, differences in drug treatment, patient diagnostic criteria and outcome evaluation between RCTs, as well as poor data quality or lack of RCTs data. Knowledge of the reported limitations may aid the design of future clinical trials and/or their meta-analyses.